BLUEJET2025-04-012025-06-30BLUEJET2025-04-012025-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares544009BLUEJETNOTLISTEDINE0KBH01020BLUE JET HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312025-07-222025-07-15INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical and API'S2025-07-2211:58:002025-07-2212:25:00Not applicablefalsefalseThe Company has not made any default with respect to loan and debt securities2025-04-012025-06-30UnauditedStandalone35475800008254000036301200001078900000075007000017426000069000005698000033441000024015200001228600000012286000002980000001890000031690000009117000000000911700000091170000034693000025.265.26005.265.261. The above financial results of the Company for the three months ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on July 22, 2025. Further, the above financial results have been reviewed by the Statutory Auditor of the Company. <BR> 2. The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products. <BR> 3.The results for the three months ended March 31, 2025 are balancing figure between the audited financial statements for the financial year ended March 31, 2025 and published unaudited results for nine months ended December 31, 2024. <BR> 4. The Company does not have any subsidiaries, associates, or joint ventures as on June 30, 2025. Consequently, the preparation of consolidated financial statements is not applicable.Other Operating expenses334410000000